Two issues should be noted when designing a clinical trial to evaluate BCG effects on COVID-19

Two issues should be noted when designing a clinical trial to evaluate BCG effects on COVID-19

Bibliographic Details
Main Authors:	Wenping Gong, Yinping Liu, Yong Xue, Li Zhuang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-05-01
Series:	Frontiers in Immunology
Subjects:	Bacillus Calmette-Guérin (BCG) tuberculosis (TB) COVID-19 clinical trial latent tuberculosis infection (LTBI)
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1207212/full

Similar Items

The Interferon-Gamma Release Assay versus the Tuberculin Skin Test in the Diagnosis of <i>Mycobacterium tuberculosis</i> Infection in BCG-Vaccinated Children and Adolescents Exposed or Not Exposed to Contagious TB
by: Magdalena Druszczynska, et al.
Published: (2023-02-01)

Research progress on specific and non-specific immune effects of BCG and the possibility of BCG protection against COVID-19
by: Jingli Du, et al.
Published: (2023-01-01)

Defined Antigen Skin Test for Bovine Tuberculosis Retains Specificity on Revaccination With Bacillus Calmette–Guérin
by: Saraswathi Subramanian, et al.
Published: (2022-04-01)

Osteomielitis de tibia secundaria a la vacuna BCG en un paciente pediátrico inmunocompetente. Reporte de un caso
by: Javier Eugenio Dal Lago, et al.
Published: (2020-05-01)

HUBUNGAN RIWAYAT STATUS IMUNISASI BACILLE CALMETTE-GUÉRIN (BCG) DENGAN KEJADIAN TUBERKULOSIS (TB) PADA ANAK DI BADAN LAYANAN UMUM DAERAH RUMAH SAKIT UMUM CUT MEUTIA ACEH UTARA TAHUN 2015
by: Hedya Nadhrati Surura, et al.
Published: (2018-02-01)

Disseminated BCG sepsis following intravesical therapy for Bladder Carcinoma: A case report and review of literature
by: Oreoluwa Oladiran, et al.
Published: (2020-03-01)

Evolution of the Bacillus Calmette-Guérin scar Russia and Moreau strains in newborns: A brazilian cohort
by: Ramon Andrade de Souza, et al.
Published: (2023-08-01)

Practical considerations for a TB controlled human infection model (TB-CHIM); the case for TB-CHIM in Africa, a systematic review of the literature and report of 2 workshop discussions in UK and Malawi [version 2; peer review: 2 approved, 1 approved with reservations]
by: Keertan Dedha, et al.
Published: (2023-06-01)

Practical considerations for a TB controlled human infection model (TB-CHIM); the case for TB-CHIM in Africa, a systematic review of the literature and report of 2 workshop discussions in UK and Malawi [version 1; peer review: 2 approved, 1 approved with reservations]
by: Keertan Dedha, et al.
Published: (2023-02-01)

In silico Analysis of Peptide-Based Biomarkers for the Diagnosis and Prevention of Latent Tuberculosis Infection
by: Peng Cheng, et al.
Published: (2022-06-01)

Immune interaction between SARS-CoV-2 and Mycobacterium tuberculosis
by: Petro Booysen, et al.
Published: (2023-09-01)

Higher BCG‐induced trained immunity prevalence predicts protection from COVID‐19: Implications for ongoing BCG trials
by: Samer Singh, et al.
Published: (2022-06-01)

Acute tenosynovitis following an accidental injection of Bacille Calmette-Guérin (BCG) in a health care worker: A case report
by: Mieko Tokano, et al.
Published: (2024-03-01)

A retrospective audit of neonatal BCG vaccination in Grampian, Scotland
by: Saba Savul, et al.
Published: (2023-12-01)

Grupo Técnico de Estudos do BCG em Câncer Vacina BCG (Bacillus Calmette-Guérin)
by: Humberto Torloni, et al.
Published: (2023-08-01)

Tuberculosis and Risk of Emphysema among US Adults in the NHANES I Epidemiologic Follow-Up Study Cohort, 1971–1992
by: Anita Joshi, et al.
Published: (2023-12-01)

Carcinoma In Situ (CIS): Is There a Difference in Efficacy between Various BCG Strains? A Comprehensive Review of the Literature
by: Andres Llano, et al.
Published: (2024-01-01)

Tuberculosis infection among children under six in contact with smear positive cases: A study in a hyper endemic area of Iran
by: Mahdi Afshari, et al.
Published: (2023-02-01)

Tuberculosis vaccine developments and efficient delivery systems: A comprehensive appraisal
by: Rasoul Hoseinpour, et al.
Published: (2024-02-01)

The safety of BCG revaccination in the context of COVID-19
by: Adriana Sánchez-García, et al.
Published: (2023-12-01)

Dual Nature of Relationship between Mycobacteria and Cancer
by: Marek Fol, et al.
Published: (2021-08-01)

BCG Vaccine—The Road Not Taken
by: Coad Thomas Dow, et al.
Published: (2022-09-01)

From immunology to artificial intelligence: revolutionizing latent tuberculosis infection diagnosis with machine learning
by: Lin-Sheng Li, et al.
Published: (2023-11-01)

Non-Tuberculous Mycobacteria Interference with BCG-Current Controversies and Future Directions
by: Deepshikha Verma, et al.
Published: (2020-11-01)

BCG Vaccine Protection against TB Infection among Children Older than 5 Years in Close Contact with an Infectious Adult TB Case
by: Angeliki Syggelou, et al.
Published: (2020-10-01)

Childhood lupus vulgaris after Bacillus Calmette–Guérin vaccine
by: Sarah Hamdy Soliman, et al.
Published: (2023-01-01)

The association of blood metals with latent tuberculosis infection among adults and adolescents
by: Jinyi Wu, et al.
Published: (2023-11-01)

Nanocages engineered from Bacillus Calmette-Guerin facilitate protective Vγ2Vδ2 T cell immunity against Mycobacterium tuberculosis infection
by: Jiang Pi, et al.
Published: (2022-01-01)

DIFFERENT CHARACTERISTICS OF INFECTION WITH MYCOBACTERIA IN GRANULOMA CELLS FROM MICE WITH LATENT TUBERCULOSIS INFECTION AND IN BONE MARROW AND PERITONEAL MACROPHAGES AFTER BCG VACCINE APPLICATION IN VITRO
by: E. G. Ufimtseva
Published: (2014-08-01)

A Modified Bacillus Calmette-Guérin (BCG) Vaccine with Reduced Activity of Antioxidants and Glutamine Synthetase Exhibits Enhanced Protection of Mice despite Diminished in Vivo Persistence
by: Douglas S. Kernodle, et al.
Published: (2013-01-01)

Cyclic di-AMP as endogenous adjuvant enhanced BCG-induced trained immunity and protection against Mycobacterium tuberculosis in mice
by: Huanhuan Ning, et al.
Published: (2022-08-01)

Assessment of adherence to pre-vaccination precautions and AEFI reporting practices during BCG vaccination in 4 hospitals in Ghana
by: Peter Yamoah, et al.
Published: (2023-01-01)

Vaccines against Tuberculosis: Where Are We Now?
by: Shruti Srivastava, et al.
Published: (2023-05-01)

BCG induced lower urinary tract symptoms during treatment for NMIBC—Mechanisms and management strategies
by: Georgia Bourlotos, et al.
Published: (2024-01-01)

Case Report with Systematic Literature Review on Vascular Complications of BCG Intravesical Therapy for Bladder Cancer
by: Brianna King, et al.
Published: (2022-10-01)

Establishment of an in vitro model of monocyte-like THP-1 cells for trained immunity induced by bacillus Calmette-Guérin
by: Jin-Chuan Xu, et al.
Published: (2024-04-01)

Revisiting the Chingleput BCG vaccination trial for the impact of BCG revaccination on the incidence of tuberculosis disease
by: Banurekha Velayutham, et al.
Published: (2023-01-01)

Diminished Short-Term Efficacy of Reduced-Dose Induction BCG in the Treatment of Non-Muscle Invasive Bladder Cancer
by: David A. Ostrowski, et al.
Published: (2023-07-01)

Intravesical BCG immunotherapy: Sepsis and multiorgan failure developed after traumatic catheterization
by: Tufan Cicek, et al.
Published: (2014-02-01)

A case of post-BCG therapy renal granuloma concurrent with ureteral carcinoma
by: Tatsuya Otaki, et al.
Published: (2023-03-01)